Back Back
ProCE Banner Activity

CME

Updates in Retinal Disease Care: Keeping an Eye on Emerging Anti-VEGF Therapies & Improved Outcomes

Video

The program, “Updates in Retinal Disease Care: Keeping an Eye on Emerging Anti-VEGF Therapies and the Potential for Improved Patient Outcomes” will deliver much-needed, up-to-date information on evidence-based strategies for dosing available anti-VEGF therapies and for integrating newly approved therapies into practice; with reviews of current clinical data from emerging retinal disease therapies.

AGENDA
Welcome and Introduction
Current State of Retinal Disease Management
Clinical Updates for New and Emerging Retinal Disease Therapies
Q&A Session and Activity Roundup

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Physicians: Maximum of 1.00 Medical Knowledge MOC point

Released: December 20, 2022

Expiration: December 20, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Nancy Holekamp

Nancy Holekamp, MD

Professor of Clinical Ophthalmology and Visual Sciences
Washington University School of Medicine
St Louis, MO
Director of Retina Services
Pepose Vision Institute
Chesterfield, MO

Carl Regillo

Carl Regillo, MD

Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, PA

Provided by

Jointly provided by the Potomac Center for Medical Education and Rockpointe

ProCE Banner
ProCE Banner

Supporters

Supported by an educational grant from Genentech, a member of the Roche Group.

Genentech, a member of the Roche Group

Target Audience

This activity is intended for ophthalmologists and clinicians who manage patients with retinal disease.

Learning Objectives

At the conclusion of this education, participants should be able to:

  • Assess risk/benefits of fixed, frequent dosing intervals versus individualized dosing intervals for anti-VEGF therapies

  • Select anti-VEGF dosing intervals that provide the best potential outcomes for patients with retinal disease

  • Assess the safety and efficacy of recently approved and emerging retinal disease therapies

Disclosure

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.

Faculty, Authors, and Content Developers
The faculty, authors and content developers reported the following relevant financial relationships with ineligible companies:

Primary Author

Nancy Holekamp, MD

Professor of Clinical Ophthalmology and Visual Sciences
Washington University School of Medicine
St Louis, MO
Director of Retina Services
Pepose Vision Institute
Chesterfield, MO

Nancy Holekamp, MD: Consulting Fee: AGTC, Allergan, Annexon, Apellis, Bayer, Cardinal, Clearside Biosciences, EyePoint, Gemini, Genentech, Gyroscope, Nacuity, NGM, Notal Vision, Novartis, Ocuphire, Outlook Therapeutics, Regeneron, Thea, Stealth Biosciences; Contracted Research: Gemini, Gyroscope, Genentech, Notal Vision; Speaker's Bureau: Apellis, Genentech, Allergan, Regeneron, Spark; Stock Holder: Nacuity, Gemini, Apellis

Carl Regillo, MD

Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, PA

Carl Regillo, MD: Consulting Fee: Adverum, Allergan, Annexon, B & L, Chengdu Kanghong, Clearside, EyePoint, Genentech, Graybug, Iveric, Kodiac, Lineage, Merck, NGM; Contracted Research: Adverum, Allergan, Annexon, Astellis, Chengdu Kanghong, EyePoint, Genentech, Graybug, Iveric, Kodiac, Lineage, NGM, Notal, Novartis, Opteha; Stock Shareholder: Ocugen, Iveric

Planners and Managers
The planners and managers reported the following relevant financial relationships with ineligible companies: 

Chad Williamson, MS, MBA, CMPP: Has no relevant financial relationships

Content Reviewers
The content reviewers reported the following relevant financial relationships with ineligible companies: 

Katie Propst, PhD: Has no relevant financial relationships

FDA DISCLOSURE
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Instructions for Credit

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.

Accreditation

PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN DESIGNATION CREDIT STATEMENT
The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME/MOC credit or the evaluation, please email contact@potomacme.org

ABO MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, earns credit toward the Lifelong Learning requirement for the American Board of Opthalmology's Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABO MOC points, your information will be shared with the ABO through PCME's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABO records.